Browsing by Author Hardingham, Jennifer

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2014Can we accurately report PTEN status in advanced colorectal cancer?Lee, Chee Khoon; Broadbridge, Vy; Cooper, John; Hardingham, Jennifer; Hocking, Christopher; Price, Timothy; Ruszkiewicz, Andrew; Tebbutt, Niall; Townsend, Amanda; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials CentreCan we accurately report PTEN status in advanced colorectal cancer?, BMC Cancer, vol.14, 1, 2014,pp 1-7
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerGebski, Val; Lee, Chee Khoon; Mann, Kristy; Simes, Robert John; Wilson, Kate; Bruhn, M; Cunningham, David; Hardingham, Jennifer; Price, Timothy; Robinson, B; Tebbutt, Niall; Townsend, Amanda; van Hazel, Guy; Weickhardt, Andrew; Wrin, Joseph; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCorrelation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, British Journal of Cancer, vol.112, 6, 2015,pp 963-970
2011Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal CancerCummins, Michelle; Lee, Chee; Chua, Ann; Hardingham, Jennifer; Murone, Carmel; Price, Timothy; Shivasami, Aravind; Tebbutt, Niall C; Townsend, Amanda; Weikhardt, Andrew; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreImpact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer, Journal of Clinical Oncology, vol.29, 19, 2011,pp 2675-2682
2014Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancerLee, Chee Khoon; Arentz, Georgia; Bruhn, Maressa; Cunningham, David; Hardingham, Jennifer; Hocking, Christopher; Price, Timothy; Shivasami, Aravind; Tebbutt, Niall C; Townsend, Amanda; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials CentreProangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer, International Journal of Cancer, vol.135, 3, 2014,pp 731-741
2013Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumabLee, Chee; Simes, Robert John; Wilson, Katherine; Hardingham, Jennifer; Murone, Carmel; Price, Timothy; Tebbutt, Niall; Townsend, Amanda; Weickhardt, Andrew; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Science Faculty AdminPrognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab, Cancer Medicine, vol.2, 3, 2013,pp 277-285